{
    "id": 20419,
    "fullName": "ALK C1156F",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ALK C1156F lies within the protein kinase domain of the Alk protein (UniProt.org). C1156F has been demonstrated to occur as a secondary drug resistance mutation in the context of NPM1-ALK (PMID: 25749034, PMID: 30322862), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 13404,
                    "pubMedId": 30322862,
                    "title": "Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322862"
                },
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "C1156F",
    "createDate": "03/28/2016",
    "updateDate": "03/07/2020",
    "referenceTranscriptCoordinates": {
        "id": 102004,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29222392C>A",
        "cDna": "c.3467G>T",
        "protein": "p.C1156F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5486,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20881,
                "profileName": "NPM1 - ALK ALK C1156F"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5416,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156F were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20881,
                "profileName": "NPM1 - ALK ALK C1156F"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5495,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20881,
                "profileName": "NPM1 - ALK ALK C1156F"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5480,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK C1156F in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20881,
                "profileName": "NPM1 - ALK ALK C1156F"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5427,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20881,
                "profileName": "NPM1 - ALK ALK C1156F"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5436,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20881,
                "profileName": "NPM1 - ALK ALK C1156F"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5421,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to ASP3026 in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20881,
                "profileName": "NPM1 - ALK ALK C1156F"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5414,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK C1156F and D1203N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20896,
                "profileName": "NPM1 - ALK ALK C1156F ALK D1203N"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5423,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20896,
                "profileName": "NPM1 - ALK ALK C1156F ALK D1203N"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5502,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20896,
                "profileName": "NPM1 - ALK ALK C1156F ALK D1203N"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5491,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with C1156F and D1203N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20896,
                "profileName": "NPM1 - ALK ALK C1156F ALK D1203N"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5479,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20896,
                "profileName": "NPM1 - ALK ALK C1156F ALK D1203N"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5432,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20896,
                "profileName": "NPM1 - ALK ALK C1156F ALK D1203N"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5440,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20896,
                "profileName": "NPM1 - ALK ALK C1156F ALK D1203N"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20879,
            "profileName": "ALK C1156F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20881,
            "profileName": "NPM1 - ALK ALK C1156F",
            "profileTreatmentApproaches": [
                {
                    "id": 16838,
                    "name": "Crizotinib",
                    "profileName": "NPM1 - ALK ALK C1156F"
                }
            ]
        },
        {
            "id": 20896,
            "profileName": "NPM1 - ALK ALK C1156F ALK D1203N",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102004,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29222392C>A",
            "cDna": "c.3467G>T",
            "protein": "p.C1156F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}